ANN ARBOR — NanoBio Corp. announced Wednesday the closing of an $11 million Series C financing, including full participation from its existing investor syndicate.
Proceeds from the financing will be used to advance the company’s development programs for herpes labialis (cold sores), cystic fibrosis and nanoemulsion-based vaccines for respiratory syncytial virus (RSV) and genital herpes (HSV2).
“The closing of this round demonstrates a strong commitment from our investors in support of our ongoing efforts to move several product candidates toward commercialization,” said David Peralta, CEO of NanoBio. “Our topical therapeutic programs continue to show tremendous promise to enable new products that can effectively treat drug-resistant pathogens and avoid the concerning safety risks associated with oral therapies.”
Peralta added, “In addition, recent studies with our vaccine technology highlight key advantages for developing new vaccines for widespread respiratory and sexually transmitted diseases. Our unique ability to elicit both systemic immunity and mucosal immunity at the sites where these viruses enter the body could prove essential in the development of vaccines for RSV, HSV2 and other diseases.”
With the closing of this Series C financing, NanoBio’s technology platform has benefited from more than $130 million in funding to date, approximately half of which have come from non-dilutive sources.
NanoBio is a privately-held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal & intramuscular vaccines derived from its patented NanoStat nanotechnology. The company’s lead product candidates are treatments for herpes labialis, onychomycosis (toenail fungus), vaginitis and cystic fibrosis, as well as several nanoemulsion-based vaccines.